Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spergualin SCHEMBL155207 | 1.00 | TACR1 (1.00) | TACR1TACR3 | |
| Spergualin SCHEMBL2141936 | 1.00 | TACR1 (1.00) | TACR1TACR3 | |
| SCHEMBL13455243 | 0.94 | TACR1 (0.88) | TACR1TACR3 | |
| SCHEMBL3213158 | 0.94 | TACR1 (0.88) | TACR1TACR3 | |
| SCHEMBL3213164 | 0.94 | TACR1 (0.88) | TACR1TACR3 | |
| SCHEMBL15680033 | 0.94 | TACR1 (0.88) | TACR1TACR3 | |
| SCHEMBL19442726 | 0.93 | TACR1 (0.86) | TACR1TACR3 | |
| SCHEMBL4564061 | 0.89 | TACR1 (0.80) | TACR1TACR3 | |
| SCHEMBL4440310 | 0.89 | TACR1 (0.80) | TACR1TACR3 | |
| SCHEMBL4437054 | 0.89 | TACR1 (0.80) | TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4510290-B2 | — | — | 2010-07-21 | — | — | JP | claimed |
| US-7713984-B2 | Pharmaceutical uses | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | claimed |
| US-20100055176-A1 | Method of Treating Fibromyalgia or Associated Functional Symptoms of Fibromyalgia | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | claimed |
| US-20080161329-A1 | Pharmaceutical uses | NOVARTIS AG (CH) | 2008-07-03 | — | — | US | claimed |
| US-20070155759-A1 | Pharmaceutical uses | FARBER LOTHAR | 2007-07-05 | — | — | US | claimed |
| US-6949257-B2 | Pharmaceutical compositions | NOVARTIS AG (CH) | 2005-09-27 | — | — | US | claimed |
| US-20050096334-A1 | Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome | FARBER LOTHAR (DE) | 2005-05-05 | — | — | US | claimed |
| EP-1082119-B1 | MICROEMULSION PRECONCENTRATES CONTAINING A PIPERIDINE SUBSTANCE P ANTAGONIST | NOVARTIS AG (CH) | 2004-01-07 | — | — | EP | claimed |
| US-20030152626-A1 | New pharmaceutical compositions | NOVARTIS AG (CH) | 2003-08-14 | — | — | US | claimed |
| US-20030092735-A1 | Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome | FARBER LOTHAR (DE) | 2003-05-15 | — | — | US | claimed |
| US-20020156099-A1 | New pharmaceutical compositions | LANG STEFFEN (CH) | 2002-10-24 | — | — | US | claimed |
| JP-2002523363-A | — | — | 2002-07-30 | — | — | JP | claimed |
| EP-1107744-A2 | USE OF SUBSTANCE P ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME AND/OR FIBROMYALGIA AND USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME | Novartis AG (CH) | 2001-06-20 | — | — | EP | claimed |
| EP-1082119-A1 | MICROEMULSION PRECONCENTRATES CONTAINING A PIPERIDINE SUBSTANCE P ANTAGONIST | Novartis AG (CH) | 2001-03-14 | — | — | EP | claimed |
| WO-2000010545-A2 | USE OF SUBSTANCE P ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME AND/OR FIBROMYALGIA AND USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME | NOVARTIS AG (CH) | 2000-03-02 | — | — | WO | claimed |
| WO-1999061025-A1 | MICROEMULSION PRECONCENTRATES CONTAINING A PIPERIDINE SUBSTANCE P ANTAGONIST | NOVARTIS AG (CH) | 1999-12-02 | — | — | WO | claimed |
| US-5965562-A | TREATING DISORDERS INDUCED BY SUBSTANCE P AND MIGRAINE HEADACHE | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | claimed |
| EP-0707006-B1 | Aroyl-piperidine derivatives | NOVARTIS AG (CH) | 1999-04-07 | — | — | EP | claimed |
| WO-1997045119-A1 | USE OF SUBSTANCE P ANTAGONISTS FOR TREATING SOCIAL PHOBIA | NOVARTIS AG (CH) | 1997-12-04 | — | — | WO | claimed |
| EP-0707006-A1 | Aroyl-piperidine derivatives | CIBA-GEIGY AG (CH) | 1996-04-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155759-A1 | Pharmaceutical uses | TACR1, NPSR1, HTR5A | TACR1 1/4885TACR3 398/4885 |
| US-20100055176-A1 | Method of Treating Fibromyalgia or Associated Functional Symptoms of Fibromyalgia | FAAH, FPR1, NPFFR1 | TACR1 11/4885TACR3 259/4885 |
| US-20080161329-A1 | Pharmaceutical uses | TACR1, NPSR1, HTR5A | TACR1 1/4885TACR3 398/4885 |
| US-20050096334-A1 | Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome | TACR1, NPSR1, TACR2 | TACR1 1/4885TACR3 27/4885 |
| US-20030092735-A1 | Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome | TACR1, NPSR1, NPFFR1 | TACR1 1/4885TACR3 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.